Contact
searchSearch
HMP Global

Hepatology Excellence Forum

Hepatology
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Sid Barritt
How I Treat
How I Treat MASLD/MASH: Dr Sidney Barritt on Pharmacotherapy
01/08/2026
A. Sidney Barritt, MD
Dr Barritt discusses how he approaches the treatment of MASLD and MASH, both with medical therapies and lifestyle adaptations.
Dr Barritt discusses how he approaches the treatment of MASLD and MASH, both with medical therapies and lifestyle adaptations.
Dr Barritt discusses how he...
01/08/2026
Gastroenterology
Expert Insights
Expert Roundtable on MASLD/MASH: Part 1
01/02/2026
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart...
01/02/2026
Gastroenterology
Alan Bonder
Conference Coverage
Alan Bonder, MD, on New Therapies for Pruritis in Liver Disease
08/26/2025
Alan Bonder, MD
Dr Bonder recaps news from the European Association for the Study of the Liver meeting on new therapies being investigated for the relief of pruritis in patients with primary biliary cholangitis.
Dr Bonder recaps news from the European Association for the Study of the Liver meeting on new therapies being investigated for the relief of pruritis in patients with primary biliary cholangitis.
Dr Bonder recaps news from the...
08/26/2025
Gastroenterology
How I Treat MASLD/MASH: A Sidney Barritt, MD
Sid Barritt
Videos
How I Treat MASLD/MASH: A Sidney Barritt, MD
07/23/2025
Dr Barritt explains how he works with patients (MASH) to to encourage and implement lifestyle interventions that can ameliorate metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis.
Dr Barritt explains how he works with patients (MASH) to to encourage and implement lifestyle interventions that can ameliorate metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis.
Dr Barritt explains how he works...
07/23/2025
Gastroenterology
Alan Bonder
Videos
Alan Bonder, MD, on Updates in Autoimmune Liver Disease
07/10/2025
Alan Bonder, MD
Dr Bonder reviews presentations from the European Association for Liver Diseases meeting providing updates on treatments for autoimmune liver diseases.
Dr Bonder reviews presentations from the European Association for Liver Diseases meeting providing updates on treatments for autoimmune liver diseases.
Dr Bonder reviews presentations...
07/10/2025
Gastroenterology
Video
Expert Roundtable: Staging and Treating NASH and MASLD
02/20/2025
Alan Bonder, MD; Gordon Jiang, MD; Hirsh Trivedi, MD
In part 2 of this video roundtable on NASH and MASLD, Drs Alan Bonder, Gordon Jiang, and Hirsh Trivedi discuss the staging of these conditions and lifestyle changes that patients can make to improve outcomes.
In part 2 of this video roundtable on NASH and MASLD, Drs Alan Bonder, Gordon Jiang, and Hirsh Trivedi discuss the staging of these conditions and lifestyle changes that patients can make to improve outcomes.
In part 2 of this video...
02/20/2025
Gastroenterology
Blanca Lizaolo-Mayo
How I Treat Lean MASH
Metabolic-associated steatohepatitis (MASH) and its precursor, metabolic-associated steatotic liver disease (MASLD), were called, until recently, nonalcoholic fatty liver diseases.
Video
Expert Roundtable: Identifying Patients at Risk of NASH and MASLD
01/23/2025
Alan Bonder, MD; Hirsh Trivedi, MD; Gordon Jiang, MD
Alan Bonder, MD, Hirsh Trivedi, MD, and Gordon Jiang, MD, discuss the importance of identifying features of metabolic syndrome when assessing patients for potential metabolic dysfunction-associated liver disease--and starting the process at...
Alan Bonder, MD, Hirsh Trivedi, MD, and Gordon Jiang, MD, discuss the importance of identifying features of metabolic syndrome when assessing patients for potential metabolic dysfunction-associated liver disease--and starting the process at...
Alan Bonder, MD, Hirsh Trivedi,...
01/23/2025
Gastroenterology
Hirsh Trivedi
How I Treat NASH (MASH)
From nutritional guidance to new medications to bariatic surgery, Dr Hirsh Trivedi reviews the many available options for treating patients diagnosed with metabolic-associated fatty liver...

News

Research Highlights
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Cumulative Social Risk Linked to Poorer Survival in Stage III Colorectal Cancer
01/14/2026
Jessica Garlewicz
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Conference Coverage
E-Cigarette Use and Risk of Peptic Ulcer Disease: Findings from a National Cohort
10/27/2025
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at...
10/27/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology
Research Highlights
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
10/01/2025
Stephanie Holland
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized,...
10/01/2025
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use